SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

The meme coin experienced a dramatic decline in value immediately following its launch, with many traders labeling the rapid drop as a classic rug pull. Community members are expressing widespread skepticism and mocking participants who invested in the project, while debating the broader implications of politically-themed crypto assets.

OpenAI

OpenAI is trending as investors monitor ongoing reports of a confidential IPO filing, which has sparked speculation about valuation targets and the potential for a large-scale market debut. Discussions also highlight leadership departures and safety concerns involving AI agent autonomy, alongside interest in the company's partnerships with hardware and infrastructure providers.

WorldFinancial

The conversation surrounding the crypto token is heavily polarized, with many traders viewing the asset as a speculative scam tied to the Trump family, while others remain bullish, citing an extremely low token float and potential catalysts like a pending bank charter and regulatory developments as reasons for an imminent price breakout. Skeptics point to significant losses and ongoing litigation to argue that the project is a grift, leading to fragmented sentiment marked by intense debate over whether current low prices represent a major buying opportunity or a permanent decline.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is receiving significant attention as traders debate the company's financial health, specifically concerns regarding cash flow and heavy capital expenditures for AI infrastructure. Community sentiment remains highly polarized, with many bulls pointing to strong earnings and a massive contract backlog as evidence of future growth, while bears emphasize the potential supply overhang from a pre-scheduled stock sale plan by Executive Chair Larry Ellison.

Anthropic

Anthropic is trending due to significant anticipation surrounding its planned initial public offering, with discussions frequently highlighting the company's aggressive revenue growth and its competitive position against other major AI labs. The conversation also centers on reports of massive infrastructure investments, strategic partnerships, and ongoing debates regarding the company's valuation and the broader market impact of a potential public listing.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is gaining momentum as the company expands its commercial footprint, most notably through the recent activation of its seventh qualified treatment center. Investors are largely focused on the company's long-term commercial execution and the growth of its patient treatment capacity, despite some community debate regarding the current pace of patient onboarding and overall share price performance.

VeChain is a public Layer-1 blockchain designed for real-world applications. Founded in 2015, its VeChainThor network supports enterprise and consumer use cases involving supply chains, product provenance, sustainability, digital product passports, tokenized incentives and verifiable data.  VeChainThor combines EVM-compatible smart contracts with a dual-token model, native fee delegation and multi-clause transactions. VET is the network’s native asset and staking collateral, while VTHO is used to pay transaction fees and execute smart contracts.  VeChain’s ecosystem includes VeBetter, an app platform that rewards verified positive actions; StarGate, its NFT-based staking platform; VeWorld, its self-custody wallet; and VeWorld.ai, its AI-agent platform. In its April 2026 roadmap, VeChain reported that VeBetter had reached 5.3 million users, more than 50 live applications and over 50 million verified actions.  VeChain has also worked with organizations including Walmart China, DNV, PwC, Boston Consulting Group and UFC across enterprise, sustainability and consumer initiatives.

Vechain

VeChain is experiencing high levels of negativity and frustration from traders as the token remains in a prolonged downtrend, with many expressing disappointment over its performance relative to other assets. While some investors remain committed to long-term holding or are using the low prices to accumulate more, the conversation is dominated by skepticism regarding project leadership, tokenomics, and the likelihood of a significant price recovery.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is trending as investors monitor ongoing discussions about a potential mega-merger with AstraZeneca, with community sentiment divided between the prospects of a major acquisition and the company's standalone growth potential through its oncology portfolio and recent regulatory approvals. Meanwhile, discussions regarding the company's patent cliffs and its reliance on pipeline development remain focal points for traders debating its long-term valuation.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is receiving attention due to a series of defense-related contract wins and strategic partnerships, including successful U.S. Army testing and a collaborative deal with Israel Aerospace Industries. Investors are debating the company's long-term potential as a defense software provider, while some traders monitor the high short interest and potential for a squeeze.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is receiving attention following a supply chain-related food safety investigation involving jalapeños, with community sentiment divided between those viewing the price decline as a buying opportunity and those criticizing the company's food quality. Traders are debating whether the reaction is an overblown market panic, given that the chain quickly removed the affected produce and authorities have reported no ongoing safety concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio, Inc. (NASDAQ:IBIO) Given Consensus Recommendation of "Buy" by Analysts

Shares of iBio, Inc. (NASDAQ:IBIO - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are covering the firm, MarketBeat reports. One research analyst has...

iBio (IBIO) Projected to Post Quarterly Earnings on Friday

iBio (NASDAQ:IBIO) will be releasing its Q3 2026 earnings before the market opens on Friday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-1-ibio-inc-stock-3...

iBio (NASDAQ:IBIO) Earns Buy Rating from Chardan Capital

Chardan Capital restated a "buy" rating and issued a $5.00 target price on shares of iBio in a report on Thursday...

iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close Trust Gap

iBio (NASDAQ:IBIO) is seeking to narrow what it views as a growing trust gap between the promise of generative AI in drug discovery and the high cost and long timelines of bringing a drug to market...

IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia

Equity

iBio stated that IBIO-600 has been approved by Australia’s Therapeutic Goods Administration to initiate a Phase 1 study in overweight and obese adult participants.

iBio, Inc. (NASDAQ:IBIO) Given Average Recommendation of "Buy" by Analysts

iBio, Inc. (NASDAQ:IBIO - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are presently covering the company, Marketbeat.com reports. One research...

iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded iBio from a "sell" rating to a "hold" rating in a report on Saturday...

Insider Buying: iBio (NASDAQ:IBIO) CFO Buys 24,835 Shares of Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of $2.02 per...

iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran bought 24,835 shares of the company's stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of...

Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock

iBio, Inc. (NASDAQ:IBIO - Get Free Report) insider Martin Brenner purchased 12,336 shares of the stock in a transaction dated Thursday, March 19th. The stock was purchased at an average cost of $2.02...

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

iBio Inc

Neutral Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$1.21
Prev Close	$1.23
Open	$1.24
Dividend Yield	0.00%
50-Day Moving Average	$1.41
Beta	1.49
Avg. Volume	692,665.87
PE Ratio	-2.66

52-Week High	$3.82
52-Week Low	$0.7708
Market Capitalization	$73.33M
EPS (Annual)	-$0.3176
Price to Book	0.78
Revenue Per Employee	$4,347.83

Feed

News

Sentiment

Fundamentals

Info

IBIO Fundamentals